WO2005041877A3 - Method of inhibiting rejection following organ transplantation - Google Patents
Method of inhibiting rejection following organ transplantation Download PDFInfo
- Publication number
- WO2005041877A3 WO2005041877A3 PCT/US2004/035874 US2004035874W WO2005041877A3 WO 2005041877 A3 WO2005041877 A3 WO 2005041877A3 US 2004035874 W US2004035874 W US 2004035874W WO 2005041877 A3 WO2005041877 A3 WO 2005041877A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- organ transplantation
- rejection following
- following organ
- inhibiting rejection
- organ
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51525403P | 2003-10-29 | 2003-10-29 | |
US60/515,254 | 2003-10-29 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2005041877A2 WO2005041877A2 (en) | 2005-05-12 |
WO2005041877A3 true WO2005041877A3 (en) | 2005-06-16 |
WO2005041877A9 WO2005041877A9 (en) | 2005-08-11 |
Family
ID=34549383
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/035874 WO2005041877A2 (en) | 2003-10-29 | 2004-10-28 | Method of inhibiting rejection following organ transplantation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005041877A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030215889A1 (en) | 2002-03-20 | 2003-11-20 | Simard J. Marc | Non-selective cation channel in neural cells and methods for treating brain swelling |
US8980952B2 (en) | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
CN101043891A (en) | 2004-09-18 | 2007-09-26 | 巴尔的摩马里兰大学 | Therapeutic agents targeting the nc ca-atp channel and methods of use thereof |
GB0427827D0 (en) * | 2004-12-20 | 2005-01-19 | Randox Lab Ltd | Method of diagnosis |
EP3103451A1 (en) * | 2007-01-12 | 2016-12-14 | University of Maryland, Baltimore | Targetting ncca-atp channel for organ protection following ischemic episode |
US9073997B2 (en) | 2007-02-02 | 2015-07-07 | Vegenics Pty Limited | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis |
EP2167107B1 (en) | 2007-06-22 | 2016-12-14 | University of Maryland, Baltimore | Inhibitors of ncca-atp channels for therapy |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
US20140050694A1 (en) * | 2012-08-20 | 2014-02-20 | Wisconsin Alumni Research Foundation | Method of Treating Transplant Rejection and Autoimmune Diseases |
US20160169890A1 (en) * | 2013-05-20 | 2016-06-16 | The Trustees Of Columbia University In The City Of New York | Tracking donor-reactive tcr as a biomarker in transplantation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547959A (en) * | 1992-12-22 | 1996-08-20 | American Home Products Corporation | Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements |
WO1998051344A1 (en) * | 1997-05-12 | 1998-11-19 | The Kennedy Institute Of Rheumatology | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
-
2004
- 2004-10-28 WO PCT/US2004/035874 patent/WO2005041877A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5547959A (en) * | 1992-12-22 | 1996-08-20 | American Home Products Corporation | Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements |
WO1998051344A1 (en) * | 1997-05-12 | 1998-11-19 | The Kennedy Institute Of Rheumatology | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
Also Published As
Publication number | Publication date |
---|---|
WO2005041877A9 (en) | 2005-08-11 |
WO2005041877A2 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005015006D1 (en) | ||
TW200602078A (en) | Uses of anti-CTLA-4 antibodies | |
WO2005102392A3 (en) | Combinations for treating hiv infection | |
WO2005107726A3 (en) | Method for the treatment of back pain | |
WO2002028867A3 (en) | Ethers of 7-desmethylrapamycin for use in immunosuppression | |
MXPA03006557A (en) | Method and apparatus to remove substances from vessels of the heart and other parts of the body to minimize or avoid renal or other harm or dysfunction. | |
WO2005028475A3 (en) | Compositions useful as inhibitors of protein kinases | |
NZ527076A (en) | Graft rejection inhibitors used in combination with immunosuppressants | |
WO2005110481A3 (en) | Prolongation of survival of an allograft by inhibiting complement activity | |
WO2006034001A3 (en) | Methods of treating hiv infection | |
WO2004031129A3 (en) | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | |
WO2005041877A3 (en) | Method of inhibiting rejection following organ transplantation | |
WO2001078653A3 (en) | Graft rejection inhibition with ccr2 inhibitors | |
WO2006047841A3 (en) | Engineering with homing factors | |
IL157841A0 (en) | Activation of natural killer cells by adenosine a3 receptor agonists | |
DE60335202D1 (en) | Chaperonin-10-immunosuppression | |
WO2003102162A3 (en) | Novel tolerogenic dendritic cells and therapeutic uses therefor | |
HK1071079A1 (en) | Use of soluble fgl2 as an immunosuppressant | |
WO2005089736A3 (en) | Methods for treating inflammatory and autoimmune diseases | |
WO2000053148A3 (en) | Methods and compositions for treating erectile dysfunction | |
MXPA02005069A (en) | Tr3 specific binding agents and methods for their use. | |
WO2001094586A3 (en) | Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof | |
EP2332563A3 (en) | Use of BAFF to treat sepsis | |
WO2003082203A3 (en) | Elastin prevents occlusion of body vessels by vascular smooth muscle cells | |
WO2001045680A3 (en) | Cd45 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/22-22/22; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
122 | Ep: pct application non-entry in european phase |